| 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-08-14 | 417.80万 | 11.02亿 | 2.41% | | 2025-08-13 | 716.88万 | 10.97亿 | 2.38% | | 2025-08-12 | 966.00万 | 10.90Z | 2.37% | | 2025-08-11 | 202.13万 | 10.81亿 | 2.35% | | 2025-08-08 | -543.28万 | 10.79亿 | 2.35% | 融券方面，当日融券卖出1.15万股，融券偿还1200.0股，融券净卖出1.03万股，融券余量49.8万股，近20 个交易日中有11个交易日出现融券净卖出。 | 交易日 | 融券冷卖用(股) | | 融券余量(股) | 融券余额(元) | | --- | --- | --- | --- | --- | | 2025-08-14 | | 1.03万 | 49.80万 | 343.62万 | | 2025-08-13 | | -1300.0 | 48.77万 | 338.46 ...

资金流向方面，今日主力资金净流出3661.80万元，占比成交额11.54%。其中，超大单净流出673.08万 元、占成交额2.12%，大单净流出2988.73万元、占成交额9.42%，中单净流出流入921.56万元、占成交 额2.9%，小单净流入2740.24万元、占成交额8.63%。 金融界消息 截至2025年8月13日收盘，上海莱士（002252）报收于6.94元，上涨0.14%，换手率0.69%， 成交量45.79万手，成交金额3.17亿元。 通过天眼查大数据分析，上海莱士血液制品股份有限公司共对外投资了25家企业，参与招投标项目690 次，知识产权方面有商标信息40条，专利信息38条，此外企业还拥有行政许可362个。 上海莱士最新一期业绩显示，截至2025一季报，公司营业总收入20.06亿元、同比减少2.45%，归属净利 润5.66亿元，同比减少25.20%，扣非净利润5.70亿元，同比减少3.52%，流动比率5.014、速动比率 3.080、资产负债率6.25%。 来源：金融界 天眼查商业履历信息显示，上海莱士血液制品股份有限公司，成立于1988年，位于上海市，是一家以从 事医药制造业为主的企业。企 ...

证券之星消息，2025年8月7日上海莱士(002252)发布公告称银河证券程培、博时基金林博鸿于2025年8月7 日调研我司。 具体内容如下： 问：公司历史沿革？ 答：公司成立于1988年，并于2008年在深交所上市。 问：目前行业内库存情况？生产周期？ 2023年12月，海尔集团与基立福签署了《战略合作及股份购买协议》，2024年1月，经基立福与海尔集团 协商一致，海尔集团下属公司海盈康作为原协议项下的承继方，海尔集团、海盈康与基立福重新签订了 《经修订及重述的战略合作及股份购买协议》，海尔集团通过海盈康收购基立福所持有公司20%股份，同 时，基立福将其持有的剩余公司6.58%股份所对应的表决权委托予海盈康行使，该交易事项已于2024年6 月完成。 2024年7月，公司召开2024年第二次临时股东大会完成公司董事会换届选举。公司控股股东变更为海盈 康，实际控制人变更为海尔集团。 问：血液制品行业情况？ 答：血液制品行业是生物制品行业的细分行业，血液制品关系人民群众的身体健康与生命安全，具有较高 的技术门槛与严格的监管要求。国家自2001年起没有批准新的血液制品生产企业，目前国内正常经营的血 液制品企业不足3 ...

2024年1至12月份，上海莱士的营业收入构成为：血液制品生产及销售占比98.48%，检测设备及试剂占 比1.48%，其他业务占比0.03%。 （文章来源：每日经济新闻） 上海莱士（SZ 002252，收盘价：6.91元）发布公告称，2025年8月7日10:00—11:00，上海莱士接受银河 证券、博时基金调研，公司副总经理、董事会秘书刘峥参与接待，并回答了投资者提出的问题。 ...

Company Overview - Shanghai Raist Blood Products Co., Ltd. was established in 1988 and listed on the Shenzhen Stock Exchange in 2008. In December 2023, Haier Group signed a strategic cooperation and share purchase agreement with Kilibof, acquiring 20% of the company’s shares through its subsidiary, Haiyingkang. The transaction was completed in June 2024, resulting in a change of controlling shareholder to Haiyingkang and actual controller to Haier Group [2][3]. Industry Situation - The blood products industry is a sub-sector of the biopharmaceutical industry, characterized by high technical barriers and strict regulatory requirements. Since 2001, no new blood product manufacturing enterprises have been approved in China, with fewer than 30 companies currently operating [3]. - In 2024, there were over 300 plasma collection stations in China, with a total plasma collection exceeding 13,000 tons, showing significant growth compared to 2023, although there remains a gap between supply and actual demand [3]. - Human albumin is the most significant product in terms of domestic sales, with a high proportion of imports. Imported human albumin is currently the only permitted human-derived blood product in China [3]. Company Goodwill - The company's goodwill primarily arises from the acquisition of other stable and well-performing enterprises in the same industry. The company conducts annual impairment testing of goodwill in compliance with regulatory requirements [4]. Sales and Market Dynamics - Domestic sales of human albumin have slightly slowed due to medical insurance policies and supply-demand dynamics. However, there remains a rigid demand for human albumin, which is used in various medical conditions [5]. - The blood products industry currently has some inventory among companies and distributors, with production and inspection cycles being relatively long [6]. - Prices of blood products have been affected by policy factors and supply-demand relationships, leading to some price reductions since the second half of last year [7]. Innovation and R&D - The company is advancing its "plasma expansion" and "plasma reduction" strategies, focusing on safety, quality, and efficiency, while increasing investment in basic research, clinical translation, and industrial upgrades [8]. - The company is conducting clinical research on SR604 injection, which is in Phase IIb trials. This product aims to prevent and treat hemophilia A and B, as well as factor VII deficiency [8][9]. Conclusion - The report highlights the strategic developments, market conditions, and innovation efforts of Shanghai Raist Blood Products Co., Ltd., emphasizing the company's position in a highly regulated and competitive industry.

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 陈乐奇的履历成为焦点：中国国籍，无境外永久居留权，1987年8月出生，现年38岁，硕士学历，注册 会计师。2009年本科毕业于复旦大学管理学院财务管理专业，2019年硕士研究生毕业于中欧国际工商学 院金融工商管理专业（FMBA）。 职业经历包括普华永道中天会计师事务所资深审计师、巴德医疗科技（上海）有限公司高级财务经理、 基立福医药科技（上海）有限公司财务总监。现任郑州莱士董事、GrifolsDiagnosticSolutionsInc．董 事、同路生物董事、同方莱士医药产业投资（广东）有限公司董事、广西莱士董事、上海莱士医药有限 公司财务负责人，并于2021年10月26日起担任上海莱士财务负责人。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，新浪财经《2024年度A股CFO数据报告》正式发布，全面梳理了上市公司财务总监（CFO）的薪 酬情况。数据显示，2024年A股上市公司CFO薪酬总额达42.70亿元，平均年薪为81.48万元。 报告进一步指出，医药生物行业（申万一级）CFO薪酬 ...

Core Insights - The healthcare ETF, Taikang (159760), has shown a slight increase of 0.46%, tracking the National Public Health and Healthcare Index (980016), which rose by 0.48% [1] - A new pricing mechanism for newly launched drugs has been established by the National Healthcare Security Administration, allowing high-level innovative drugs a five-year price stability period, which is expected to reverse the trend of price drops upon market entry [1] - Innovative drugs like Zebutinib from BeiGene and the dual-antibody drug from Baillie Tianheng are anticipated to drive significant revenue growth in the coming years [1][2] Industry Developments - The index constituents are experiencing a technological breakthrough, with companies like Kangfang Bio and Eli Lilly making significant advancements in drug development [2] - The AI+mRNA platform developed by CloudTop has achieved full-chain coverage from antigen design to industrial production, indicating a shift in innovative drug development paradigms [3] - The index includes companies that are directly benefiting from healthcare payment reforms and supportive policies for innovative drugs, with over 80% of the constituents poised to gain from these changes [4] Financial Performance - As of June 30, 2025, the top ten weighted stocks in the National Public Health and Healthcare Index accounted for 51.67% of the index, with companies like WuXi AppTec and Hengrui Medicine leading the way [5] - Hengrui Medicine's R&D investment ratio reached 28% in the first half of 2025, with a 50% year-on-year increase in the number of new drug approvals, indicating strong growth potential [4] Market Outlook - The healthcare ETF is expected to continue leading in the structural market of the healthcare industry, driven by the expansion of commercial insurance innovative drug catalogs and accelerated approvals for AI medical devices [4] - The index reflects the performance of listed companies in the public health and healthcare sector, focusing on prevention, testing, and treatment areas with significant potential for AI technology applications [4]

Core Viewpoint - Shanghai Laishi Blood Products Co., Ltd. has approved a share repurchase plan to enhance employee stock ownership and equity incentives, with a total repurchase amount ranging from RMB 250 million to RMB 500 million, at a maximum price of RMB 9.55 per share [1] Group 1: Share Repurchase Plan - The company plans to repurchase shares using self-owned or raised funds through centralized bidding in the secondary market [1] - The repurchase period is set for 12 months from the date of shareholder approval, with the possibility of early termination if certain conditions are met [1] Group 2: Progress of Share Repurchase - As of July 31, 2025, the company has repurchased a total of 65,321,952 shares, accounting for 0.98% of the total share capital, with a total transaction amount of approximately RMB 448.67 million [2] - The highest transaction price during the repurchase was RMB 7.09 per share, while the lowest was RMB 6.62 per share [2] Group 3: Compliance and Future Plans - The company's share repurchase activities comply with relevant regulations and guidelines set by the Shenzhen Stock Exchange and the China Securities Regulatory Commission [2][3] - The company will continue to implement the repurchase plan based on market conditions and will fulfill information disclosure obligations as required by law [3]

Group 1 - The core point of the article is that Shanghai Laishi (002252) announced a share buyback program, having repurchased a total of 65,321,952 shares as of July 31, 2025, which represents 0.98% of the company's total share capital [1]

上海莱士（002252.SZ）8月1日在投资者互动平台表示，公司研发项目情况详见公司年度报告中"研发投 入"章节。目前，公司创新研发项目之一的"SR604注射液"已进入Ⅱb期临床试验研究阶段，SR604注射 液拟用于皮下注射预防治疗血友病A和B以及凝血因子七缺乏的病人。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问公司在创新药方面有哪些项目？ ...